RxDoctor Payments Data

John Hostetter, MD

Cardiovascular Disease · Falmouth, MANPI 1518069954

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 25 payments — averaging $44.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$393
  • Boston Scientific$174
  • Stryker$120
  • Novartis$56
  • Johnson & Johnson$55
  • E.r. Squibb & Sons, L.L.C.$51
  • plus $256 from 10 others

What the payments were for

  • Food & beverage$71164%
  • Other$39336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,104 in reported general payments places this provider in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$507,380
Medicare patients
2,449
Services billed
8,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban655$944,401
XareltoRivaroxaban301$400,809
JardianceEmpagliflozin214$243,530
EntrestoSacubitril/Valsartan104$130,117
MultaqDronedarone Hcl18$34,832
Repatha SureclickEvolocumab20$24,837
Rosuvastatin Calcium559$23,198
Metoprolol Succinate1,079$22,778
Atorvastatin Calcium1,205$18,269
Ezetimibe244$13,744
FarxigaDapagliflozin Propanediol15$11,759
Diltiazem 24hr Er (Cd)Diltiazem Hcl229$9,271
LipitorAtorvastatin Calcium14$8,817
Losartan Potassium689$8,474
Nifedipine ErNifedipine253$7,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$27$953,219669 claims
Johnson & JohnsonXarelto$55$400,809301 claims
Boehringer IngelheimJardiance$22$243,530214 claims
NovartisEntresto$56$130,117104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Falmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →